CL2022002564A1 - Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) - Google Patents

Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)

Info

Publication number
CL2022002564A1
CL2022002564A1 CL2022002564A CL2022002564A CL2022002564A1 CL 2022002564 A1 CL2022002564 A1 CL 2022002564A1 CL 2022002564 A CL2022002564 A CL 2022002564A CL 2022002564 A CL2022002564 A CL 2022002564A CL 2022002564 A1 CL2022002564 A1 CL 2022002564A1
Authority
CL
Chile
Prior art keywords
combinations
low
divisional application
present
brimonidine
Prior art date
Application number
CL2022002564A
Other languages
English (en)
Inventor
Gerald Horn
Original Assignee
Eye Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Therapies Llc filed Critical Eye Therapies Llc
Publication of CL2022002564A1 publication Critical patent/CL2022002564A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a composiciones que contienen brimonidina de dosis baja y ya sea un segundo fármaco para glaucoma, una anti-histamina o un fármaco anti-inflamatorio no esteroideo. La presente invención se dirige además, a métodos para tratar glaucoma o alergias o reducir la inflamación administrando composiciones de la presente invención.
CL2022002564A 2017-06-08 2022-09-21 Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) CL2022002564A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516931P 2017-06-08 2017-06-08
US201862621082P 2018-01-24 2018-01-24

Publications (1)

Publication Number Publication Date
CL2022002564A1 true CL2022002564A1 (es) 2023-05-26

Family

ID=64562826

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019003572A CL2019003572A1 (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2022002564A CL2022002564A1 (es) 2017-06-08 2022-09-21 Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
CL2022002566A CL2022002566A1 (es) 2017-06-08 2022-09-21 Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019003572A CL2019003572A1 (es) 2017-06-08 2019-12-06 Combinaciones de brimonidina de dosis baja y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022002566A CL2022002566A1 (es) 2017-06-08 2022-09-21 Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)

Country Status (12)

Country Link
US (2) US20180353504A1 (es)
EP (1) EP3634415A4 (es)
JP (2) JP2020523312A (es)
KR (1) KR20200018580A (es)
CN (2) CN117122600A (es)
AU (2) AU2018279074B2 (es)
BR (1) BR112019025987A2 (es)
CA (1) CA3066398A1 (es)
CL (3) CL2019003572A1 (es)
MX (3) MX2019014748A (es)
SG (1) SG11201911750RA (es)
WO (2) WO2018226942A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210027410A (ko) 2018-07-03 2021-03-10 페넥 파마슈티컬스, 인크. 무수 싸이오황산나트륨의 제형
BR112022024202A2 (pt) 2020-05-27 2022-12-20 Lupin Ltd Composições oftálmicas de nano-emulsão
WO2022097731A1 (ja) * 2020-11-06 2022-05-12 アイ・セラピーズ・エル・エル・シー 眼科用液体製剤
KR102444571B1 (ko) * 2020-11-18 2022-09-19 주식회사태준제약 세티리진 및 토코페솔란을 포함하는 안과용 조성물
WO2024028816A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CN103143022A (zh) * 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法
CN100463668C (zh) * 2005-05-09 2009-02-25 凌沛学 可逆性热凝胶化水性药物组合物
ITMI20070890A1 (it) * 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
US9629852B2 (en) * 2007-10-16 2017-04-25 Sun Pharma Advanced Research Company Ltd. Ophthalmic composition comprising a prostaglandin
US20180360825A1 (en) * 2008-08-01 2018-12-20 Eye Therapies, Llc Vasoconstriction compositions and methods of use
US8283350B2 (en) * 2008-08-01 2012-10-09 Alpha Synergy Development, Inc. Compositions and methods for reducing capillary permeability
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
EP2408453B1 (en) 2009-03-17 2022-01-05 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス, インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US8445526B2 (en) * 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
EP2694048B1 (en) * 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
US20130203813A1 (en) * 2011-05-04 2013-08-08 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
BR112014001118A2 (pt) * 2011-07-20 2017-02-14 Allergan Inc combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
US20140194527A1 (en) * 2012-02-29 2014-07-10 Rohto Usa, Inc. Geranylgeranylacetone formulations and retinal delivery thereof
US9248135B2 (en) * 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9833441B2 (en) * 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
WO2015138786A1 (en) * 2014-03-12 2015-09-17 The Trustees Of Columbia University In The City Of New York Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents
CN108350021A (zh) * 2015-09-08 2018-07-31 视点医疗公司 用于治疗眼科疾病的化合物和制剂
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
US20200197398A1 (en) * 2017-06-08 2020-06-25 Eye Therapies, Llc Netarsudil and low-dose brimonidine combination and uses thereof

Also Published As

Publication number Publication date
MX2019014748A (es) 2020-08-03
BR112019025987A2 (pt) 2020-06-30
EP3634415A1 (en) 2020-04-15
JP2020523312A (ja) 2020-08-06
CL2019003572A1 (es) 2020-04-24
AU2018279074A1 (en) 2020-01-16
CN110996954A (zh) 2020-04-10
EP3634415A4 (en) 2021-03-17
SG11201911750RA (en) 2020-01-30
WO2019236148A1 (en) 2019-12-12
CL2022002566A1 (es) 2023-05-26
MX2022008479A (es) 2022-08-02
MX2022008478A (es) 2022-08-02
AU2023282222A1 (en) 2024-01-04
US20180353504A1 (en) 2018-12-13
RU2019144001A3 (es) 2022-03-05
CN117122600A (zh) 2023-11-28
RU2019144001A (ru) 2021-07-09
AU2018279074B2 (en) 2023-12-14
KR20200018580A (ko) 2020-02-19
JP2023055823A (ja) 2023-04-18
WO2018226942A1 (en) 2018-12-13
CA3066398A1 (en) 2018-12-13
US20220233524A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2020000747A1 (es) Formulaciones de niraparib.
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
PA8566501A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
CL2017001913A1 (es) Composición tópica curativa
UY27656A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinación para el tratamiento de enfermedades
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112023006312A2 (pt) Composto, métodos para preparar o composto, composição farmacêutica e uso do composto
CO2022014499A2 (es) Moduladores de nlrp3
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
CL2020001738A1 (es) Preparación de absorción percutánea para el tratamiento de la demencia que contiene donepezilo.
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
CL2021000282A1 (es) Inhibidores de ckd8/19
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca